DETAILED ACTION
Applicant’s amendment and Arguments/Remarks received on 09 July 2026 have been entered. Claims 1-3, 5-10, 13-14, 16-24, 27, 29-30, and 34-39 were previously pending in the application. Claims 6, 8, 34, and 37-38 have been cancelled, and no new claims have been added by Applicant. Claims 1-3, 5, 7, 9-10, 13-14, 16-24, 27, 29-30, 35-36, and 39 are currently pending in the application. Claim 1 is an independent claim.
Claims 1-3, 5, 7, 9-10, 13-14, 16-24, 27, 29-30, 35-36, and 39 are currently pending and under examination in the instant application. An action on the merits follows.
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Priority
The present application is a CON of 17/855,423, filed 30 June 2022, now abandoned, which is a CON of 17/499,232, filed 12 October 2021, now U.S. Patent No. 11,672,874, which is a CIP of International Application No. PCT/US2020049240, filed 03 September 2020, which claims priority to U.S. Provisional Application Nos. 62/895,441, filed 03 September 2019, 62/908,800, filed 01 October 2019, and 63/039,261, filed 15 June 2020.
Thus, the earliest possible priority for the instant application is 03 September 2019.
Information Disclosure Statement
The information disclosure statement filed 15 July 2026 has been considered by the Examiner.
37 CFR 1.821-1.825
This notice for failing to comply with the requirements of 37 CFR 1.821 through 1.825 for Figure 3B disclosing amino acid and/or nucleotide sequences but not including any sequence identifiers is withdrawn in view of Applicant’s amendment to the specification such that the Brief Description of the Drawings not recited the SEQ ID NOs for the sequences depicted in Figure 3B.
Drawings
The objection to the drawings of the disclosure for the partial views for Figure 5 that appear on several sheets are followed by "continued" instead of a capital letter such as FIG. 5A, FIG. 5B, etc. is withdrawn in view of the amendment to the drawings. The replacement drawing sheets filed 09 July 2026 have been entered.
Specification
The amendment to the specification of the disclosure filed 09 July 2026 has been entered.
Claim Objections
The objection to amended and cancelled claims 6, 8-10, 21-23 for reciting abbreviations without first writing out the terms in claims 6, 8-10, and 21-23 and also for duplicating “(I)” in claim 22 is withdrawn in view of the amendment to claims.
Claim Rejections - 35 USC § 112(b)
The rejection of amended, previously presented, original, and cancelled claims 1-3, 5-10, 13-14, 16-24, 27, 29-30, and 34-39 under 35 U.S.C. 112(b) as failing to particularly point out and distinctly claim the subject matter which the inventor(s) regards as the invention for multiple issues of indefiniteness is withdrawn in view of Applicant’s amendments to the claims.
*The following new rejection is necessitated by Applicant’s amendments to the claims.
Amended claims 22-23 are newly rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Amended claim 22 now recites, “wherein the first RNA molecule further comprises (a) a promoter sequence, or a reverse complement thereof, (b) a 5’ UTR sequence, (c) a 3’ UTR sequence and a poly A sequence; wherein (I) the promoter sequence is upstream of the 5’ UTR sequence, and (II) the 3’ UTR sequence and the poly A sequence are downstream of the promoter sequence or the reverse complement thereof, and the RNA sequence encoding the exogenous human therapeutic polypeptide or the reverse complement thereof.” The comma (“,”) between “the promoter sequence or the reverse complement thereof” and “and the RNA sequence encoding the exogenous human therapeutic polypeptide or reverse complement thereof” renders the claim indefinite in that it is unclear whether a comma is missing following “the promoter sequence” such that “or the reverse complement thereof” is meant to be offset by commas such that the 3’ UTR is downstream of both the promoter and the RNA sequence encoding the exogenous human therapeutic polypeptide (or their respective reverse complements) or whether “and the RNA sequence encoding the exogenous human therapeutic polypeptide or reverse complement thereof” is meant to be a separate limitation which is incomplete. As such, the metes and bounds of the claim cannot be determined.
Amended claim 23 recites the limitation "the RNA molecule" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 23 is dependent on amended claim 22, which is dependent on amended independent claim 1, wherein each of claims 1 and 22 recite multiple RNA molecules. As such, it is unclear to which RNA molecule “the RNA molecule” is referring. Therefore, the metes and bounds of the claim cannot be determined.
Claim Rejections - 35 USC § 112(a)
The rejection of amended and cancelled claims 6 and 8-10 under 35 U.S.C. 112(a) for reciting functional fragments of ORF1p and/or ORF2p is withdrawn in view of Applicant’s amendments to the claims such that the claims no longer recite functional fragments thereof.
The rejection of amended claim 22 under 35 U.S.C. 112(a) for new matter is withdrawn in view of Applicant’s amendments to the claims such that the new matter was deleted from the claim.
The rejection of amended, previously presented, original, and cancelled claims 1-3, 5-10, 13-14, 16-24, 27, 29-30, and 34-39 under 35 U.S.C. 112(a) for failing to comply with the enablement requirement is withdrawn in view of Applicant’s amendments to the claims such that the claims are now directed to a method of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell of a target human cell population instead of a method of expressing an exogenous human therapeutic polypeptide from a genomically integrated DNA sequence of a cells of a target human cell population.
*The following new rejection is necessitated by Applicant’s amendments to the claims.
Amended, previously presented, and original claims 1-3, 5, 7, 9-10, 13-14, 16-24, 27, 29-30, 35-36, and 39 are newly rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for:
A method of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell of a target human cell population, the method comprising:
(a) contacting a plurality of exogenous RNA molecules to the target human cell population, wherein a cell of the target human cell population uptakes the plurality of exogenous RNA molecules and wherein the plurality of exogenous RNA molecules do not comprise any antibiotic selection marker, and wherein the plurality of exogenous RNA molecules comprise:
a first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide;
a mobile genetic element comprising an RNA sequence encoding a LINE1 Open Reading Frame (ORF)1p polypeptide and an RNA sequence encoding a LINE1 ORF2p polypeptide with target-primed reverse transcription (TPRT) activity, wherein the LINE1 ORF2p polypeptide with TPRT activity comprises a reverse transcriptase (RT) domain and an endonuclease (EN) domain, wherein
the EN domain lacks EN activity, and
the mobile genetic element is not operably linked to a promoter, and
the mobile genetic element is derived from a mammal;
at least one guide RNA (gRNA) sequence or a polynucleotide encoding the at least one gRNA sequence, wherein the at least one gRNA sequence targets a target site within the genomic locus in the cell of the target human cell population; and
a second RNA molecule comprising a sequence encoding a Cas9 nickase capable of generating a gRNA guided single stranded break at the genomic locus, thereby generating an endonuclease nicked site comprising a 3'-OH terminus;
(b) translating the mobile genetic element to produce the LINE1 ORF1p polypeptide and the LINE1 ORF2p polypeptide with TPRT activity;
(c) priming the first RNA molecule at the 3'-OH terminus of the endonuclease nicked site generated by the Cas9 nickase and reverse transcribing the RNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide or the RNA sequence encoding the exogenous human therapeutic polypeptide via the TPRT activity of the LINE1 ORF2p polypeptide translated in step (b), thereby producing the DNA sequence encoding the exogenous human therapeutic polypeptide or a DNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide at the genomic locus;
wherein the first RNA molecule comprises a 3’ flanking sequence comprising a genomic DNA priming sequence;
and wherein the first RNA molecule comprises a 5’ or 3’ flanking sequence comprising a binding site for the LINE1 ORF2p polypeptide with TPRT activity;
does not reasonably provide enablement for:
A method of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at any genomic locus of a cell of a target human cell population, the method comprising:
(a) contacting a plurality of exogenous RNA molecules to the target human cell population, wherein a cell of the target human cell population uptakes the plurality of exogenous RNA molecules and wherein the plurality of exogenous RNA molecules do not comprise any antibiotic selection marker, and wherein the plurality of exogenous RNA molecules comprise:
any first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide;
a mobile genetic element comprising an RNA sequence encoding a LINE1 Open Reading Frame (ORF)1p polypeptide and an RNA sequence encoding a LINE1 ORF2p polypeptide with target-primed reverse transcription (TPRT) activity, wherein the LINE1 ORF2p polypeptide with TPRT activity comprises a reverse transcriptase (RT) domain and an endonuclease (EN) domain, wherein
the EN domain lacks EN activity, and
the mobile genetic element is not operably linked to a promoter, and
the mobile genetic element is derived from a mammal;
at least one guide RNA (gRNA) sequence or a polynucleotide encoding the at least one gRNA sequence, wherein the at least one gRNA sequence targets a target site within the genomic locus in the cell of the target human cell population; and
a second RNA molecule comprising a sequence encoding a Cas9 nickase capable of generating a gRNA guided single stranded break at the genomic locus, thereby generating an endonuclease nicked site comprising a 3'-OH terminus;
(b) translating the mobile genetic element to produce the LINE1 ORF1p polypeptide and the LINE1 ORF2p polypeptide with TPRT activity;
(c) priming the first RNA molecule at the 3'-OH terminus of the endonuclease nicked site generated by the Cas9 nickase and reverse transcribing the RNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide or the RNA sequence encoding the exogenous human therapeutic polypeptide via the TPRT activity of the LINE1 ORF2p polypeptide translated in step (b), thereby producing the DNA sequence encoding the exogenous human therapeutic polypeptide or a DNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide at the genomic locus;
wherein the first RNA molecule does not comprise a 3’ flanking sequence comprising a genomic DNA priming sequence;
and wherein the first RNA molecule does not comprise a 5’ or 3’ flanking sequence comprising a binding site for the LINE1 ORF2p polypeptide with TPRT activity.
The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.
This rejection comprises two (2) separate issues:
1) the absence of an enabling disclosure for priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell using any first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide without a 3’ flanking sequence comprising a sequence complimentary to a genomic DNA priming sequence at the genomic locus; and
2) the absence of an enabling disclosure for priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell using any first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide without a 5’ or 3’ flanking sequence comprising a binding site for the LINE1 ORF2p polypeptide with TPRT activity.
These issues were identified by the Office after analysis of the disclosure provided by the specification. The Office has analyzed the specification in direct accordance to the factors outlined in In re Wands, namely 1) the nature of the invention, 2) the state of the prior art, 3) the predictability of the art, 4) the amount of direction or guidance present, and 5) the presence or absence of working examples, and presented detailed scientific reasons supported by publications from the prior art for the finding of a lack of enablement for the scope of the instant methods. The Wands analysis and supporting specific evidence are presented below for each of the identified issues.
As a first issue (1), the specification does not provide an enabling disclosure for priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell using any first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide without a 3’ flanking sequence comprising a sequence complimentary to a genomic DNA priming sequence at the genomic locus.
The broadest independent claim, claim 1, recites a method of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell of a target human cell population comprising: contacting (a) a plurality of exogenous RNA molecules to the target human cell population, wherein the plurality of exogenous RNA molecules comprise (i) a first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide; (ii) a mobile genetic element comprising an RNA sequence encoding a LINE1 ORF1p and a n RNA sequence encoding a LINE1 ORF2p polypeptide with TPRT activity, wherein the LINE 1 ORF2p polypeptide with TPRT activity lacks endonuclease activity; (iii) at least one gRNA targeting a target site within the genomic locus; and (iv) a second RNA molecule comprising a sequence encoding a Cas9 nickase, thereby generating an endonuclease nicked site comprising a 3’-OH terminus; (b) translating the mobile genetic element to produce LINE1 ORF1p and LINE1 ORF2p; and (b) priming the first RNA molecule at the 3’-OH terminus and reverse transcribing the RNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide or the RNA sequence encoding the exogenous human therapeutic polypeptide via the TPRT activity of the LINE2 ORF2p, thereby producing the DNA sequence encoding the exogenous human therapeutic polypeptide or a DNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide at the genomic locus. Claims 2-3, 5, 7, 9-10, 13-14, 16-24, 27, 29-30, 35-36, and 39 depend on claim 1.
The specification discloses wherein the general mechanism of LINE1 retrotransposition includes wherein the ORF2p cleaves at a consensus sequence TAAAA such that the poly A at the 3’ end of the mRNA hybridizes at the target site and primes the reverse transcriptase activity of the ORF2 protein [00134, 00268, Figure 1A, 1E]. The specification also teaches wherein the 3’ region of the retrotransposon comprises a genomic DNA priming sequence [00323, 00330, 00331]. Additionally, the specification teaches wherein one or more target specific nucleotides may be added at the priming end of the RNA priming region [00343].
In support of an argument of unexpected results, Applicant has referenced a post-filing publication, Wang, which teaches the combination of an EN(-)-ORF2p protein with a Cas9 nickase for the targeted integration of a transgene into a genomic DNA sequence [Wang et al. 2025, EMBO Reports, 26, 1062-1683, IDS, cited in a prior action]. However, the Wang publication does not support an enabling disclosure for the instantly claimed invention. Wang teaches the criticality of a sequence at the 3’ end of an RNA for hybridization with the genomic locus to allow the target sequence proximal to the 3’-OH terminus (i.e., 3’ flaps) to anneal to, and thereby prime, the exogenous RNA for the reverse transcriptase activity of the ORF2p to synthesize the payload cDNA [pg 1062 col 2 ¶ 3, pg 1063 col 1 ¶ 3-4, Figure 1B].
The art at the time of filing further teaches the necessity of hybridization with the 3’-OH terminal sequence at the target site to prime ORF2p-mediated reverse transcription of the exogenous RNA for cDNA synthesis, wherein the selected gRNA targets a unique site on chromosome 8 that contains the appropriate sequences to both direct site-specific Cas9 cleavage and provide a T-rich sequence for A-tail annealing of the Alu RNA for reverse transcription by L1 ORF2p [Ade et al. 2018, Gene, Vol. 642, 188-198, cited in a prior action, pg 189 col 1 ¶ 3, pg 195 col 1 ¶ 2- col 2 ¶ 1, Figure 5B].
Neither the specification nor the art at the time of filing teaches priming an exogenous RNA at a genomic locus in the absence of a sequence at the 3’ end of the exogenous RNA which can hybridize with the 3’ flap of the nicked genomic DNA. Thus, in view of Applicant’s lack of disclosure for priming and reverse transcribing an exogenous RNA at a genomic locus in the absence of a hybridizing sequence, the art recognized criticality of hybridizing sequences for priming TPRT activity to produce a cDNA copy of the exogenous RNA, and the breadth of the claims, the skilled artisan would have considered priming and reverse transcribing an exogenous RNA sequence at a genomic locus of a cell without a sequence complementary to the genomic locus as highly unpredictable. As such, it would have required undue experimentation to practice the scope of Applicant’s invention as claimed.
As a second issue (2), the specification does not provide an enabling disclosure for priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell using any first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide without a 5’ or 3’ flanking sequence comprising a binding site for the LINE1 ORF2p polypeptide with TPRT activity.
The broadest independent claim, claim 1, recites a method of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide at a genomic locus of a cell of a target human cell population comprising: contacting (a) a plurality of exogenous RNA molecules to the target human cell population, wherein the plurality of exogenous RNA molecules comprise (i) a first RNA molecule comprising an RNA sequence that is a reverse complement of a sequence encoding the exogenous human therapeutic polypeptide or an RNA sequence encoding the exogenous human therapeutic polypeptide; (ii) a mobile genetic element comprising an RNA sequence encoding a LINE1 ORF1p and a n RNA sequence encoding a LINE1 ORF2p polypeptide with TPRT activity, wherein the LINE 1 ORF2p polypeptide with TPRT activity lacks endonuclease activity; (iii) at least one gRNA targeting a target site within the genomic locus; and (iv) a second RNA molecule comprising a sequence encoding a Cas9 nickase, thereby generating an endonuclease nicked site comprising a 3’-OH terminus; (b) translating the mobile genetic element to produce LINE1 ORF1p and LINE1 ORF2p; and (b) priming the first RNA molecule at the 3’-OH terminus and reverse transcribing the RNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide or the RNA sequence encoding the exogenous human therapeutic polypeptide via the TPRT activity of the LINE2 ORF2p, thereby producing the DNA sequence encoding the exogenous human therapeutic polypeptide or a DNA sequence that is the reverse complement of the sequence encoding the exogenous human therapeutic polypeptide at the genomic locus. Claims 2-3, 5, 7, 9-10, 13-14, 16-24, 27, 29-30, 35-36, and 39 depend on claim 1.
The specification discloses wherein the one or more polynucleic acids comprises a 5’ UTR sequence, 3’ UTR sequence, and a polyA sequence, wherein the 5’UTR, 3’UTR, or the polyA sequence comprises a binding site for a human ORF2p [0018, 0077-0081, 0101-0104, 00280-00281, 0316-0317]. The specification also teaches wherein the general mechanism of LINE1 retrotransposition includes wherein the ORF2p binds the 3’ end of its own mRNA through the poly A tail, cleaves at a consensus sequence TAAAA such that the poly A at the 3’ end of the mRNA hybridizes at the target site and primes the reverse transcriptase activity of the ORF2 protein [00134, 00268-00269, Figure 1A, 1E].
In support of an argument of unexpected results, Applicant has referenced a post-filing publication, Wang, which teaches the combination of an EN(-)-ORF2p protein with a Cas9 nickase for the targeted integration of a transgene into a genomic DNA sequence [Wang et al. 2025, EMBO Reports, 26, 1062-1683, IDS, cited in a prior action]. However, the Wang publication does not support an enabling disclosure for the instantly claimed invention. Wang teaches that ORF2p association with the L1 mRNA facilitates reverse transcription of the L1 element, wherein the endonuclease ORF2p cleaves at a redundant 5’TTTT/A3’ consensus sequence, initiation a target-primed reverse transcription (TPRT) process mediated by the RT domain of ORF2p that converts the LI1 mRNA into cDNA [pg 1062 col 2 ¶ 3].
The art at the time of filing further teaches the necessity of ORF2 binding to a highly conserved stem-loop structure within the 3’ UTR of target RNAs for target recognition and reverse transcription leading to retrotransposition [Grechishnikova & Poptsova 2016, BMC Genomics, 17(1), 992, 1-17, IDS, abstract, pg 3 col 1 ¶ 3, pg 6 col 1 ¶ 3- pg 7 col 1 ¶ 2, pg 8 col 1 ¶ 2, pg 13 col 2 ¶ 3].
Neither the specification nor the art at the time of filing teaches reverse transcribing an exogenous RNA at a genomic locus by an ORF2p RT activity in the absence of a sequence at the 3’ end of the exogenous RNA which can be recognized and bound by the ORF2p polypeptide. Thus, in view of Applicant’s lack of disclosure for priming and reverse transcribing an exogenous RNA at a genomic locus in the absence of an ORF2p binding site within the target RNA, the art recognized criticality of ORF2p binding to target RNA sequences for TPRT activity to produce a cDNA copy of the exogenous RNA, and the breadth of the claims, the skilled artisan would have considered priming and reverse transcribing an exogenous RNA sequence at a genomic locus of a cell in the absence of an ORF2p binding sequence within the target RNA as highly unpredictable. As such, it would have required undue experimentation to practice the scope of Applicant’s invention as claimed.
Insofar as Applicant’s arguments apply to this new grounds of rejection, Applicant argues that:
the application as originally filed provides ample guidance for a site specific priming and reverse transcription of an exogenous sequence at a genomic locus by teaching that the retrotransposon machinery itself is sufficient for priming and reverse transcription of an exogenous sequence at a nuclease excision site, for example in [0331] which recites:
“The retrotransposon protein coding sequence, and the 3' UTR may be a complete and sufficient unit for delivering the heterologous nucleic acid sequence within the genome of the cell, and comprise the retrotransposable elements, such as an endonuclease, a reverse transcriptase, a sequence in the 3' UTR for binding to and priming the genomic DNA at the region cleaved by the endonuclease to start reverse transcribing and incorporating the heterologous nucleic acid.” [0330 in specification filed 09 July 2026]; and
the specification teaches the claimed embodiment (e.g., [0331]) and the limitation of priming and reverse transcribing an exogenous RNA sequence encoding an exogenous human therapeutic polypeptide, as evidenced by Wang Fig 1B(2), which indicates that the claimed subject matter does not require 2 gRNAs to prime and reverse transcribe an exogenous RNA sequence.
However, this is not agreed.
Regarding Applicant’s argument 1), note that the independent claim 1 as written does not require a 3’ UTR, and further does not require a sequence in the 3' UTR for binding to and priming the genomic DNA at the region cleaved by the endonuclease to start reverse transcribing and incorporating the heterologous nucleic acid. As such, Applicant’s argument is supporting the lack of enablement by indicating the requirement for the 3’ UTR sequences for ORF2p binding and priming to achieve reverse transcription. Further, although the gRNA is required to target the genomic locus where the priming and RT are required to occur, there is no requirement for a sequence in the exogenous RNA which is complementary to the specific genomic locus where the priming and reverse transcription is required to occur.
Regarding Applicant’s argument 2), note that although Wang Figure 1B(2) indicates that a second gRNA is not required for priming and reverse transcribing, Wang Figure 1B(2) also indicates that an overlapping reverse complementary sequence is required for the priming the exogenous RNA for reverse transcription at the genomic locus.
Therefore, Applicant’s arguments do not overcome the scope of enablement rejection under 35 U.S.C. 112(a).
Conclusion
No claim is allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. KATIE L PENNINGTON whose telephone number is (703)756-4622. The examiner can normally be reached M-Th 8:30 am - 5:30 pm, Friday 8:30 am - 12:30 pm CT.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria G. Leavitt can be reached at (571) 272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
DR. KATIE L. PENNINGTON
Examiner
Art Unit 1634
/KATIE L PENNINGTON/Examiner, Art Unit 1634
Dr. A.M.S. Wehbé
/ANNE MARIE S WEHBE/Primary Examiner, Art Unit 1634